Turning Point Therapeutics, Inc.
TPTX · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $31 | $25 | $0 | $0 |
| % Growth | 23.3% | – | – | – |
| Cost of Goods Sold | $0 | $25 | $0 | $0 |
| Gross Profit | $31 | $0 | $0 | $0 |
| % Margin | 100% | 0% | – | – |
| R&D Expenses | $193 | $113 | $58 | $21 |
| G&A Expenses | $76 | $73 | $20 | $5 |
| SG&A Expenses | $76 | $73 | $20 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $269 | $187 | $78 | $26 |
| Operating Income | -$237 | -$162 | -$78 | -$26 |
| % Margin | -767.3% | -647.3% | – | – |
| Other Income/Exp. Net | $1 | $5 | $6 | $1 |
| Pre-Tax Income | -$237 | -$157 | -$72 | -$25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$237 | -$157 | -$72 | -$25 |
| % Margin | -767.3% | -629.2% | – | – |
| EPS | -5.79 | -3.85 | -2.99 | -1.66 |
| % Growth | -50.4% | -28.8% | -80.1% | – |
| EPS Diluted | -5.79 | -3.85 | -2.99 | -1.66 |
| Weighted Avg Shares Out | 41 | 41 | 24 | 15 |
| Weighted Avg Shares Out Dil | 41 | 41 | 24 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $2 | $2 | $0 |
| EBITDA | -$233 | -$155 | -$71 | -$25 |
| % Margin | -754.4% | -619.6% | – | – |